肺癌分子靶点治疗的研究进展(6)
七.结语
有关肺癌发生发展分子机制的研究表明，在肺癌细胞中不但存在包括癌基因在内的多种基因的改变，而且癌细胞内的各种基本过程都存在有控制失调，这些过程包括信号传导、细胞周期、细胞凋亡、血管形成、端粒酶的稳定性以及细胞外基质的相互作用等等。抗肿瘤药物的研究在经过几十年的发展后，已由过去单纯研制杀伤型细胞毒药物过渡到今天针对新的作用机制和新的分子靶点的方法和药物的开发上来。随着人们对肺癌分子生物学研究的不断深入，一些新的、针对新的分子靶点的高效、低毒的治疗方法和治疗药物也将会暂露头角。虽然已有的肺癌分子靶点治疗的基础和临床研究已初显成效，但现有的方法和技术到目前为止尚未取得突破性的进展。道长路远，相信随着人们对肺癌分子生物学基础知识的进一步了解和新的技术手段的不断出现，肺癌的分子靶点治疗研究将会更加深入，人类在新世纪征服肺癌的前景也将充满曙光。
参考文献
1冯久贤,王瑞年. 肺癌的分子基础与临床. 中国肿瘤, 1998, 7(6):25-27
, http://www.100md.com
2Slebos, RJC, Kibbelaar, RE, Dalesio, O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med,1991, 324(20):1353-1362
3Mukhopadhyay, T, Tainsky, M, Cavander, AC, et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res,1991, 51(6):1744-1748
4Kern, JA, Schwartz, DA, Nordberg, JE, et al. p185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res,1990,,50(16):5184-5191
, 百拇医药
5Akie K, Dosaka-Akita H, Murakami A, Kawakami YA. combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer. Antisense Nucleic Acid Drug Dev, 2000 ,10(4):243-249
6Robinson, LA, Smith, LJ, Fontaine, MP, et al. C-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg, 1995,60:1583-1591
, 百拇医药
7曾益新主编，肿瘤学.人民卫生出版社，1999年，北京。
8Gibbs, JB, Oliff, A, Kohl, NE. Farnesylation inhibitors: ras research yields a potential cancer therapeutic. Cell,1994,77(2):175-178
9Adjei AA, Davis JN, Bruzek LM, et al.Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res,2001,7(5):1438-1445
10Adjei AA, Erlichman C, Davis JN, et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res, 2000 ,60(7):1871-1877
11Baselga, J, Tripathy, D, Mendelsohn, J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol,1996, 14:737-744, 百拇医药(乔贵宾 吴一龙)
有关肺癌发生发展分子机制的研究表明，在肺癌细胞中不但存在包括癌基因在内的多种基因的改变，而且癌细胞内的各种基本过程都存在有控制失调，这些过程包括信号传导、细胞周期、细胞凋亡、血管形成、端粒酶的稳定性以及细胞外基质的相互作用等等。抗肿瘤药物的研究在经过几十年的发展后，已由过去单纯研制杀伤型细胞毒药物过渡到今天针对新的作用机制和新的分子靶点的方法和药物的开发上来。随着人们对肺癌分子生物学研究的不断深入，一些新的、针对新的分子靶点的高效、低毒的治疗方法和治疗药物也将会暂露头角。虽然已有的肺癌分子靶点治疗的基础和临床研究已初显成效，但现有的方法和技术到目前为止尚未取得突破性的进展。道长路远，相信随着人们对肺癌分子生物学基础知识的进一步了解和新的技术手段的不断出现，肺癌的分子靶点治疗研究将会更加深入，人类在新世纪征服肺癌的前景也将充满曙光。
参考文献
1冯久贤,王瑞年. 肺癌的分子基础与临床. 中国肿瘤, 1998, 7(6):25-27
, http://www.100md.com
2Slebos, RJC, Kibbelaar, RE, Dalesio, O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med,1991, 324(20):1353-1362
3Mukhopadhyay, T, Tainsky, M, Cavander, AC, et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res,1991, 51(6):1744-1748
4Kern, JA, Schwartz, DA, Nordberg, JE, et al. p185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res,1990,,50(16):5184-5191
, 百拇医药
5Akie K, Dosaka-Akita H, Murakami A, Kawakami YA. combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer. Antisense Nucleic Acid Drug Dev, 2000 ,10(4):243-249
6Robinson, LA, Smith, LJ, Fontaine, MP, et al. C-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg, 1995,60:1583-1591
, 百拇医药
7曾益新主编，肿瘤学.人民卫生出版社，1999年，北京。
8Gibbs, JB, Oliff, A, Kohl, NE. Farnesylation inhibitors: ras research yields a potential cancer therapeutic. Cell,1994,77(2):175-178
9Adjei AA, Davis JN, Bruzek LM, et al.Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res,2001,7(5):1438-1445
10Adjei AA, Erlichman C, Davis JN, et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res, 2000 ,60(7):1871-1877
11Baselga, J, Tripathy, D, Mendelsohn, J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol,1996, 14:737-744, 百拇医药(乔贵宾 吴一龙)